We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
Massachusetts-based Hopewell Therapeutics closed $25 million in seed funding on June 7. The start-up aims to design lipid nanoparticles (LNPs) for delivering nucleic acid cargos to treat lung diseases.
